Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27


First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, Majeti R, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, Padda SK.

J Clin Oncol. 2019 Apr 20;37(12):946-953. doi: 10.1200/JCO.18.02018. Epub 2019 Feb 27.


CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma.

Advani R, Volkmer JP, Chao MP.

N Engl J Med. 2019 Jan 31;380(5):497-498. doi: 10.1056/NEJMc1816156. No abstract available.


The Macrophage 'Do not eat me' signal, CD47, is a clinically validated cancer immunotherapy target.

Takimoto CH, Chao MP, Gibbs C, McCamish MA, Liu J, Chen JY, Majeti R, Weissman IL.

Ann Oncol. 2019 Mar 1;30(3):486-489. doi: 10.1093/annonc/mdz006. No abstract available.


Induced pluripotent stem cell modeling of malignant hematopoiesis.

Chao MP, Majeti R.

Exp Hematol. 2019 Mar;71:68-76. doi: 10.1016/j.exphem.2019.01.002. Epub 2019 Jan 16. Review.


CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM.

N Engl J Med. 2018 Nov 1;379(18):1711-1721. doi: 10.1056/NEJMoa1807315.


Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease.

Chao MP, Gentles AJ, Chatterjee S, Lan F, Reinisch A, Corces MR, Xavy S, Shen J, Haag D, Chanda S, Sinha R, Morganti RM, Nishimura T, Ameen M, Wu H, Wernig M, Wu JC, Majeti R.

Cell Stem Cell. 2017 Mar 2;20(3):329-344.e7. doi: 10.1016/j.stem.2016.11.018. Epub 2017 Jan 12.


Myeloid Cell Origins, Differentiation, and Clinical Implications.

Weiskopf K, Schnorr PJ, Pang WW, Chao MP, Chhabra A, Seita J, Feng M, Weissman IL.

Microbiol Spectr. 2016 Oct;4(5). doi: 10.1128/microbiolspec.MCHD-0031-2016. Review.


A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab.

Chu TW, Zhang R, Yang J, Chao MP, Shami PJ, Kopeček J.

Theranostics. 2015 Apr 26;5(8):834-46. doi: 10.7150/thno.12040. eCollection 2015.


Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab.

Chao MP, Hong J, Kunder C, Lester L, Schrier SL, Majeti R.

Am J Hematol. 2015 Jan;90(1):78-81. doi: 10.1002/ajh.23791. Epub 2014 Jul 11. No abstract available.


Two faces of ET: CALR and JAK2.

Chao MP, Gotlib J.

Blood. 2014 Mar 6;123(10):1438-40. doi: 10.1182/blood-2014-01-547596.


Inhibition of lymphoma vascularization and dissemination by estrogen receptor β agonists.

Yakimchuk K, Hasni MS, Guan J, Chao MP, Sander B, Okret S.

Blood. 2014 Mar 27;123(13):2054-61. doi: 10.1182/blood-2013-07-517292. Epub 2014 Jan 27.


Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.

Chao MP.

Cancer Manag Res. 2013 Aug 23;5:251-69. doi: 10.2147/CMAR.S34273. eCollection 2013. Review.


The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PØ, Steinberg GK, Li G, So SK, Majeti R, Harsh GR, van de Rijn M, Teng NN, Sunwoo JB, Alizadeh AA, Clarke MF, Weissman IL.

Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7. doi: 10.1073/pnas.1121623109. Epub 2012 Mar 26.


The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications.

Chao MP, Weissman IL, Majeti R.

Curr Opin Immunol. 2012 Apr;24(2):225-32. doi: 10.1016/j.coi.2012.01.010. Epub 2012 Feb 4. Review.


Programmed cell removal: a new obstacle in the road to developing cancer.

Chao MP, Majeti R, Weissman IL.

Nat Rev Cancer. 2011 Dec 8;12(1):58-67. doi: 10.1038/nrc3171. Review.


Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.

Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL.

Blood. 2011 Nov 3;118(18):4890-901. doi: 10.1182/blood-2011-02-338020. Epub 2011 Aug 9.


Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker.

Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, Majeti R.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5009-14. doi: 10.1073/pnas.1100551108. Epub 2011 Mar 7.


CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R.

Blood. 2011 Feb 24;117(8):2423-32. doi: 10.1182/blood-2010-08-301945. Epub 2010 Dec 30. Retraction in: Blood. 2019 Aug 15;134(7):658.


Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47.

Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, Weissman IL.

Sci Transl Med. 2010 Dec 22;2(63):63ra94. doi: 10.1126/scitranslmed.3001375.


Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.

Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R.

Cancer Res. 2011 Feb 15;71(4):1374-84. doi: 10.1158/0008-5472.CAN-10-2238. Epub 2010 Dec 21.


Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.

Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R.

Cell. 2010 Sep 3;142(5):699-713. doi: 10.1016/j.cell.2010.07.044.


Macrophages as mediators of tumor immunosurveillance.

Jaiswal S, Chao MP, Majeti R, Weissman IL.

Trends Immunol. 2010 Jun;31(6):212-9. doi: 10.1016/ Epub 2010 May 7. Review.


CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N, Weissman IL.

Cell. 2009 Jul 23;138(2):286-99. doi: 10.1016/j.cell.2009.05.045.


CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.

Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL.

Cell. 2009 Jul 23;138(2):271-85. doi: 10.1016/j.cell.2009.05.046.


Establishment of a normal hematopoietic and leukemia stem cell hierarchy.

Chao MP, Seita J, Weissman IL.

Cold Spring Harb Symp Quant Biol. 2008;73:439-49. doi: 10.1101/sqb.2008.73.031. Epub 2008 Nov 6. Review.


The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.

Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, Jones C, Zehnder JL, Lilleberg SL, Weissman IL.

Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6224-9. Epub 2006 Apr 7.


Supplemental Content

Support Center